El 74 %
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El 74 %
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
El 74 %
de los inversores minoristas pierde dinero cuando opera CFDs con este proveedor.
Invertir conlleva riesgos y no es adecuado para todos los inversores. Los CFDs son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El 74 %
de inversores minoristas pierde dinero al operar CFDs con este proveedor.
Debes considerar si entiendes cómo funcionan los CFDs y si puedes permitirte asumir el alto riesgo de perder tu dinero.
Johnson and Johnson
Abierto
SectorSanidad
153.77 -0.52
Resumen
Variación precio
24h
Mínimo
152.41
Máximo
155.08
Ingresos | 3.4B |
|---|---|
Ventas | 20M 23B |
P/B Media del Sector | 17.455 57.333 |
BPA | 2.77 |
Rentabilidad por dividendo | 3.3 |
Margen de beneficios | 15.235 |
Empleados | 138,100 |
EBITDA | 652M 5.9B |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 Meses | +9.18% upside |
Rentabilidad por dividendo Media del Sector | 3.30% 2.63% |
|---|---|
Próximas Ganancias | 16 jul 2025 |
Fecha Próximo Dividendo | 10 jun 2025 |
Próxima Fecha de Ex Dividendo | 27 may 2025 |
Capitalización Mercado | 11B 378B |
|---|---|
Apertura anterior | 154.29 |
Cierre anterior | 153.77 |
Puntuación técnica
By Trading Central
Confianza
Bullish Evidence
Johnson and Johnson Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Johnson and Johnson previsión
Precio Objetivo
By TipRanks
9.18% repunte
Estimación a 12 Meses
Media 169.15 USD 9.18%
Máximo 185 USD
Mínimo 159 USD
De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Johnson and Johnson Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Johnson and Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
